Key result
Gene therapy for arthritis is reviewed as a potential strategy to overcome the limitations of current treatments, focusing on delivery strategies, gene transfer vectors, candidate genes, and safety.
This review summarizes recent developments in gene therapy for arthritis, highlighting its potential to overcome limitations of current systemic treatments.
Gene transfer may overcome current arthritis therapy limitations; leaves open whether preclinical promise will yield safe, effective clinical treatments.
Arthritis is among the leading causes of disability in the developed world. There remains no cure for this disease and the current treatments are only modestly effective at slowing the disease's progression and providing symptomatic relief. The clinical effectiveness of current treatment regimens has been limited by short half-lives of the drugs and the requirement for repeated systemic administration. Utilizing gene transfer approaches for the treatment of arthritis may overcome some of the obstacles associated with current treatment strategies. The present review examines recent developments in gene therapy for arthritis. Delivery strategies, gene transfer vectors, candidate genes, and safety are also discussed.
No takes yet. Share an insight, caveat, or question.
Traister et al. (2008) conducted a review in Arthritis. Gene therapy was evaluated. Gene therapy for arthritis is reviewed as a potential strategy to overcome the limitations of current treatments, focusing on delivery strategies, gene transfer vectors, candidate genes, and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: